China Sets Norms For Foreign Trial Data Submissions
Executive Summary
China's latest draft rules set conditions for accepting foreign clinical study data, discouraging ‘selective filing’. Experts see enhanced opportunities for international drug makers to register new products, especially drugs to treat critical, pediatric and rare diseases.
You may also be interested in...
China Open To Views, Change But Some Gaps Remain
Several common themes emerged from the sessions on China at this week's BIO Japan 2018 meeting in Tokyo, including the openness of the regulatory authorities there to discussions and industry suggestions on policy, the breath-taking speed of change, and some remaining gaps and unknowns surrounding a recent major structural shake-up.
China Proposes Norms For Conditional Approval, Compassionate Use
Two new proposals by the China FDA will likely accelerate regulatory approvals of novel treatments for life-threatening and rare conditions in the country. By allowing foreign study data, these proposed norms are expected to prompt international drug makers to engage with local regulators early in their global new drug development process.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.